Literature DB >> 17700999

Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran.

Zohreh Rahimi1, Asad Vaisi-Raygani, Hadi Mozafari, Hadi Kharrazi, Mansour Rezaei, Ronald L Nagel.   

Abstract

BACKGROUND: The mutation in factor V (FV) G1691A, known as factor V Leiden, and prothrombin (FII) gene G20210A are the two most prevalent causes of inherited thrombophilia. The present study reports the prevalence of factor V Leiden and the prothrombin G20210A gene mutations among healthy individuals of Kurdish ethnic background in Western Iran.
METHODS: Four hundred thirty-four healthy unrelated individuals, 255 male and 179 female, with a mean age of 28.7+/-15.5 from the Kermanshah Province of Iran were studied for prothrombin G20210A mutation. The factor V Leiden mutation was studied in 404 healthy individuals, of whom 232 were male and 172 were female. The factor V Leiden and prothrombin G20210A were detected by polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) method using Mnl I and Hind III restriction enzymes, respectively.
RESULTS: Among 434 individuals studied for prothrombin G20210A mutation seven carried this mutation as heterozygous (four female subjects and three male), giving a prevalence of 1.6% [95% confidence intervals (CI) 0.5-2.7) and an allele frequency of 0.8%. No homozygous prothrombin 20210AA was found. Factor V G1691A mutation was detected as heterozygous in 11 of 404 healthy individuals (five female and six male) and as homozygous in one male indicating a prevalence of 2.97% (95% CI 1.3-4.6) and allele frequency of 1.6%.
CONCLUSIONS: Our results indicated that the factor V Leiden and prothrombin G20210A mutations are not rare among populations of Western Iran and that the relationship between venous thrombophilia and these mutations have to be further studied in Western Iran population, which, in turn, may suggest a causal effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700999     DOI: 10.1007/s11239-007-0052-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

1.  Thrombophilic mutations in Iran.

Authors:  S Zeinali; F Duca; B Zarbakhsh; L Tagliabue; P M Mannucci
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

2.  High prevalence of factor V Leiden in healthy Jordanian Arabs.

Authors:  A Awidi; M Shannak; A Bseiso; M A Kailani; M A Kailani; N Omar; B Anshasi; N Sakarneh
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

3.  Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population.

Authors:  P Angchaisuksiri; S Pingsuthiwong; K Aryuchai; M Busabaratana; T Sura; V Atichartakarn; P Sritara
Journal:  Am J Hematol       Date:  2000-10       Impact factor: 10.047

4.  The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese.

Authors:  N Irani-Hakime; H Tamim; R Kreidy; W Y Almawi
Journal:  Am J Hematol       Date:  2000-09       Impact factor: 10.047

5.  Prevalence of the 20210 G-->A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population.

Authors:  Khaled K Abu-Amero; Carol A Wyngaard; Marios Kambouris; Nduna Dzimiri
Journal:  Arch Pathol Lab Med       Date:  2002-09       Impact factor: 5.534

6.  Ethnic differences in the prevalence of inherited thrombophilic polymorphisms in an asymptomatic Australian prenatal population.

Authors:  Joanne M Said; Shaun P Brennecke; Eric K Moses; Susan P Walker; Anthony J Borg; Jeff T Williams; John R Higgins
Journal:  Hum Biol       Date:  2006-08       Impact factor: 0.553

7.  Geographic distribution of the 20210 G to A prothrombin variant.

Authors:  F R Rosendaal; C J Doggen; A Zivelin; V R Arruda; M Aiach; D S Siscovick; A Hillarp; H H Watzke; F Bernardi; A M Cumming; F E Preston; P H Reitsma
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

8.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

9.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

Review 10.  Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis.

Authors:  Georg Endler; Christine Mannhalter
Journal:  Clin Chim Acta       Date:  2003-04       Impact factor: 3.786

View more
  14 in total

1.  Thrombophilic mutations and susceptibility to preeclampsia in Western Iran.

Authors:  Shohreh Malek-Khosravi; Zohreh Rahimi; Ziba Rahimi; Faranak Jalilvand; Abbas Parsian
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

2.  Association between apolipoprotein ε4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in Southern Iran.

Authors:  Zohreh Rahimi; Asad Vaisi-Raygani; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

3.  Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan.

Authors:  R Dajani; A Arafat; N Hakooz; Z Al-Abbadi; Al-Motassem Yousef; M El Khateeb; F Quadan
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

4.  The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.

Authors:  Zohreh Rahimi; Vahid Felehgari; Mehrali Rahimi; Hadi Mozafari; Kheirollah Yari; Asad Vaisi-Raygani; Mansour Rezaei; Shohreh Malek-Khosravi; Habibolah Khazaie
Journal:  Mol Biol Rep       Date:  2010-09-19       Impact factor: 2.316

5.  A Multiplex Allele Specific Polymerase Chain Reaction (MAS-PCR) for the Detection of Factor V Leiden and Prothrombin G20210A.

Authors:  Morteza Bagheri; Isa Abdi Rad
Journal:  Maedica (Buchar)       Date:  2011-01

6.  Prevalence of factor V Leiden in south Tunisian blood donors.

Authors:  Lobna Maalej; Basma Hadjkacem; Ikram Ben Amor; Mariem Smaoui; Ali Gargouri; Jalel Gargouri
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

7.  Prevalence of thrombotic risk factors among beta-thalassemia patients from Western Iran.

Authors:  Zohreh Rahimi; Mandana Ghaderi; Ronald L Nagel; Adriana Muniz
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

8.  The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T among G6PD deficient individuals from Western Iran.

Authors:  Hadi Mozafari; Zohreh Rahimi; Azadeh Heidarpour; Mahsa Fallahi; Adraiana Muniz
Journal:  Mol Biol Rep       Date:  2009-02-15       Impact factor: 2.316

9.  Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan.

Authors:  Rana Dajani; Raja Fatahallah; Abdelrahman Dajani; Mohammad Al-Shboul; Yousef Khader
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

10.  Prevalence of positive factor V Leiden and prothrombin mutations in samples tested for thrombophilia in Saudi Arabia.

Authors:  Fatimah Madkhaly; Abdulaziz Alshaikh; Hala Aba Alkhail; Randa Alnounou; Tarek Owaidah
Journal:  Am J Blood Res       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.